Literature DB >> 9662242

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.

M Raderer1, A Kurtaran, M Hejna, F Vorbeck, P Angelberger, W Scheithauer, I Virgolini.   

Abstract

Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [123I]VIP. In this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with histologically verified colorectal cancer underwent scanning by means of [123I]VIP (1 microg, approximately 150 MBq). Thirteen patients were free of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and 6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine physicians in a blinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with [123I]VIP. Negative VIP scans were obtained in all 13 patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to conventional radiological methods.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662242      PMCID: PMC2062941          DOI: 10.1038/bjc.1998.433

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy.

Authors:  P Schlag; B Lehner; L G Strauss; P Georgi; C Herfarth
Journal:  Arch Surg       Date:  1989-02

2.  Cancer statistics, 1994.

Authors:  C C Boring; T S Squires; T Tong; S Montgomery
Journal:  CA Cancer J Clin       Date:  1994 Jan-Feb       Impact factor: 508.702

3.  Genetic mapping of a locus predisposing to human colorectal cancer.

Authors:  P Peltomäki; L A Aaltonen; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; J S Green; J R Jass; J L Weber; F S Leach
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

4.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

Authors:  W Scheithauer; H Rosen; G V Kornek; C Sebesta; D Depisch
Journal:  BMJ       Date:  1993-03-20

Review 5.  Radiology in the detection and prevention of colorectal cancer.

Authors:  G Stevenson
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

Review 6.  Radio-immunotargeting in colorectal carcinoma.

Authors:  E J Rutgers
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

7.  Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels.

Authors:  Y Z Patt; D A Podoloff; S Curley; L Kasi; R Smith; V Bhadkamkar; C Charnsangavej
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

8.  Vasoactive intestinal peptide receptor scintigraphy.

Authors:  I Virgolini; A Kurtaran; M Raderer; M Leimer; P Angelberger; E Havlik; S Li; W Scheithauer; B Niederle; P Valent
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

9.  Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.

Authors:  I Virgolini; Q Yang; S Li; P Angelberger; N Neuhold; B Niederle; W Scheithauer; P Valent
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

10.  Probabilities of eventually developing or dying of cancer--United States, 1985.

Authors:  H Seidman; M H Mushinski; S K Gelb; E Silverberg
Journal:  CA Cancer J Clin       Date:  1985 Jan-Feb       Impact factor: 508.702

View more
  7 in total

1.  Gut peptide receptor expression in human pancreatic cancers.

Authors:  R A Ehlers; Sh Kim; Y Zhang; R T Ethridge; C Murrilo; M R Hellmich; D B Evans; C M Townsend; B Mark Evers
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

Review 2.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

3.  Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.

Authors:  V Lelievre; G Favrais; C Abad; H Adle-Biassette; Y Lu; P M Germano; G Cheung-Lau; J R Pisegna; P Gressens; G Lawson; J A Waschek
Journal:  Peptides       Date:  2007-05-18       Impact factor: 3.750

4.  High expression of peptide receptors as a novel target in gastrointestinal stromal tumours.

Authors:  Jean Claude Reubi; Meike Körner; Beatrice Waser; Luca Mazzucchelli; Louis Guillou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-18       Impact factor: 9.236

5.  Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.

Authors:  K Szepeshazi; A V Schally; K Groot; P Armatis; G Halmos; F Herbert; B Szende; J L Varga; M Zarandi
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

6.  Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library.

Authors:  Bo Tang; Zhexu Li; Dingde Huang; Lei Zheng; Qianwei Li
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

7.  Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer.

Authors:  Kang Lin; Jun Huang; Hongliang Luo; Chen Luo; Xiaojian Zhu; Fanqin Bu; Han Xiao; Li Xiao; Zhengming Zhu
Journal:  Aging (Albany NY)       Date:  2020-03-31       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.